FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc’s (NYSE:MRK) supplemental marketing…
AstraZeneca, Merck Provided Update on US Regulatory Priority Review of Lynparza in Combination With Abiraterone in Metastatic Castration-resistant Prostate Cancer
AstraZeneca and MSD today announced that the US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date by three months to provide further time for a full review of the supplementary new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of metastati
‘Florida Gov. DeSantis Calls For Grand Jury To Investigate Covid Vaccines’ – InsiderPaper
https://insiderpaper.com/florida-gov-desantis-calls-for-grand-jury-to-investigate-covid-vaccines/
Ron DeSantis, the Governor of Florida, announced his decision to appoint a grand jury to investigate the
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd). The data showed encouraging and…
AstraZeneca Announced Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients With Heavily Pretreated HR-positive, HER2-Low or Negative Metastatic Breast Cancer
First results for AstraZeneca and Daiichi Sankyo's TROP2-directed ADC in this setting reported from TROPION-PanTumor01 Phase I trial. Pivotal TROPION-Breast01 Phase III trial is ongoing, evaluating datopotamab deruxtecan in these patients in earlier lines of treatment.
Datopotamab Deruxtecan Showed Encouraging, Durable Efficacy In Patients With Heavily Pretreated HR Positive, HER2 Low Or Negative Metastatic Breast Cancer
First results for Daiichi Sankyo and AstraZeneca's TROP2 directed ADC in this setting reported from TROPION-PanTumor01 phase 1 trial
Pivotal TROPION-Breast01 phase 3 trial is ongoing, evaluating datopotamab
Guardant Health Announces Collaboration With AstraZeneca To Develop Companion Diagnostic To Identify Patients With ESR1-mutated Metastatic Breast Cancer
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today it has entered into a collaboration with AstraZeneca to pursue the development, regulatory approval and commercialization of the
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor…